(Circulation. 2007;116:e93.)
© 2007 American Heart Association, Inc.
Correspondence |
Department of Cardiology, IRCCS Fondazione Policlinico S. Matteo, University of Pavia, Pavia, Italy
Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tenn
The letter by Dr ORourke does not address correctly the findings and implications of our work on sudden death in infants that began in 1976.1 As recently specified elsewhere,2 we have repeatedly proposed a widespread ECG screening in the first month of life with the specific goal of early identification of infants affected by the long QT syndrome (LQTS). We never proposed it with the sole goal of prevention of sudden infant death syndrome, a naïve idea given that sudden infant death syndrome is multifactorial.3 Our objective has always been the prevention of sudden death caused by LQTS at whatever age it may occur. We and others4–7 have progressively demonstrated that a significant percentage of sudden infant death syndrome cases (9.5%; 95% CI, 5.8 to 14.4) are actually caused by LQTS, a highly treatable arrhythmogenic disease of genetic origin. It follows that neonatal ECG screening may allow prevention of these very early LQTS deaths, usually labeled as sudden infant death syndrome.
Contrary to what Dr ORourke infers, LQTS deaths are indeed caused by ventricular fibrillation independent of the age of the patients. This is not an assumption. The evidence that lethal arrhythmias underlie LQTS deaths is simply overwhelming. Also contrary to Dr ORourkes statement, we did not "liken [LQTS] to ischemic and other heart diseases". The rhythm found by the ambulance services, when called for a cardiac arrest, depends on the time elapsed from the onset of the episode, and after several minutes ventricular fibrillation is followed by asystole. Dr ORourkes abstract,8 published in 1998 but never followed by a full-length article, did not provide the mean time between cardiac arrest and ECG recording in his study. On the other hand, in a "proof-of-concept" case of cardiac arrest in an apparently healthy infant, later found to have a SCN5A mutation that caused LQTS,4 ventricular fibrillation was documented only because the family lived 100 yards from the local hospital.
Dr ORourke lumps ECG together with genetic screening. Neither we nor anyone else ever proposed "mass genetic screening" in newborns. In a recently completed prospective ECG study in 45 000 infants 3- to 4-weeks old, we demonstrated that 50% of those with a QTc >470 ms are LQTS mutation carriers.9 This means that the old, simple, inexpensive ECG may help select the few (<1/1000) infants in whom genetic screening would be rational.
As for health authorities, they wisely realize that neonatal ECG screening aims to prevent ventricular fibrillation in young adults, children, and adolescents, as well as in some infants. Currently, health authorities are carefully considering the implications of the high cost-effectiveness, at least in Europe, of such a screening.10
Although a program of neonatal screening may or may not be supported by individual physicians, our data leave no doubts as to the absolute right of parents of a newborn child to be informed about LQTS, an uncommon (1/2500 live births) but life-threatening disease, which is highly treatable and can be diagnosed by a simple ECG. Parents will then have the free choice to decide whether or not they wish carry out this act of cardiovascular prevention.
| Acknowledgments |
|---|
None.
| References |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |